Medical information Clinical review pending

Genetic Testing

Alg9 Gene Glycosylation Disorder Type 1L Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to identify mutations in the ALG9 gene, associated with Glycosylation Disorder Type 1L, a metabolic condition. Helps diagnose potential health risks and guide treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results: Confirm with the laboratory before booking.
Preparation: No special preparation is required for the blood draw. However, a genetic counseling session prior to testing is recommended to discuss family history and the implications of the test.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Alg9 Gene Glycosylation Disorder Type 1L Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Suspected Glycosylation Disorder Type 1L based on clinical symptoms.
✓Family history of Glycosylation Disorder Type 1L or related metabolic disorders.
✓Developmental delays or neurological abnormalities of unknown cause.
✓Recurrent or unusual infections.
✓To confirm a diagnosis suggested by other tests.
✓Genetic counseling for family planning.

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the ALG9 gene that cause Glycosylation Disorder Type 1L. It aids in the diagnosis of this metabolic disorder, which can present with a range of symptoms. Identifying the specific mutation can help confirm a diagnosis, understand the potential severity of the condition, and guide appropriate medical management and genetic counseling.

The Alg9 Gene Glycosylation Disorder Type 1L NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to Glycosylation Disorder Type 1L. This condition affects the body's ability to properly process sugars (glycosylation), which is essential for the function of many proteins and lipids. Early detection is important for managing potential health issues associated with these metabolic disorders. This test utilizes advanced Next-Generation Sequencing (NGS) technology for comprehensive analysis. It is particularly relevant for individuals with a family history of metabolic disorders or those presenting with symptoms like developmental delays or neurological issues. Understanding your genetic predisposition can inform treatment decisions and family planning.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo special preparation is required for the blood draw. However, a genetic counseling session prior to testing is recommended to discuss family history and the implications of the test.

SampleBlood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.

MethodologyNext-Generation Sequencing (NGS) of the ALG9 gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the ALG9 gene. It may not detect mutations in other genes that can cause similar symptoms. A negative result does not completely rule out a glycosylation disorder. The test may not identify all possible mutations within the ALG9 gene. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Glycosylation Disorder Type 1L is a rare metabolic condition caused by mutations in the ALG9 gene. It affects the body's ability to attach sugar molecules (glycosylation) to proteins, which is crucial for their proper function.

This test is recommended for individuals with symptoms suggestive of Glycosylation Disorder Type 1L, such as developmental delays or neurological issues, or those with a family history of the condition.

A blood sample is required for this test. We offer convenient home sample collection services in Nairobi, Mombasa, and Kisumu, as well as collection at our laboratory branches.

Turnaround time for results can vary. Please confirm the current estimated turnaround time with the laboratory before booking your test.

A positive result indicates the presence of a mutation in the ALG9 gene associated with Glycosylation Disorder Type 1L. It is important to discuss the results with your doctor or a genetic counselor to understand the implications.

Yes, genetic counseling before and after testing is highly recommended. It helps in understanding the test, interpreting results, and discussing potential implications for you and your family.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp